Verified UK Resources for Damp, Mould & Health

Here is a short, reliable, UK-verified list of resources for people worried about damp, mould and health. Each link is trustworthy, evidence-based, and not influenced by companies selling testing or “mycotoxin cleanses”.

1. NICE – Damp and Mould Guidelines

This guideline covers indoor air quality in residential buildings. It aims to raise awareness of the importance of good air quality in people's homes and how to achieve this.
🔗 https://www.nice.org.uk/guidance/NG149

2. UK Health Security Agency (UKHSA) – Damp & Mould Health Guidance

The most authoritative public health guidance used by councils, housing providers, and clinicians.
Includes:

How mould affects health
Who is at higher risk
What landlords must do
🔗https://www.gov.uk/government/publications/damp-and-mould-understanding-and-addressing-the-health-risks-for-rented-housing-providers/understanding-and-addressing-the-health-risks-of-damp-and-mould-in-the-home--2

3. Shelter – Tenant Rights on Damp and Mould

For renters needing practical, legal steps to get repairs done.
🔗Damp and mould in private rented homes
🔗Damp and mould in council and housing association homes

4. Citizens Advice – Step-by-Step Action for Damp Problems

Simple language, includes letter templates for landlords.
🔗 https://www.citizensadvice.org.uk/housing/repairs-and-housing/repairs-and-housing-conditions/whos-responsible-for-repairs/repairs-damp/

5. Housing Ombudsman – Damp & Mould Guidance for Social Housing

Very helpful for council and housing association tenants dealing with delays or poor responses.
🔗 https://www.housing-ombudsman.org.uk/damp-and-mould/

6. Awaab’s Law Information (Housing Ombudsman)

Sets strict deadlines for social landlords to investigate and fix reported damp/mould.
🔗 https://www.housing-ombudsman.org.uk/centre-for-learning/key-topics/awaabs-law/

7. Asthma + Lung UK – Mould and Breathing Problems

Good for people with asthma, COPD, ABPA or bronchiectasis.
Practical tips and when to seek medical help.
🔗 https://www.asthmaandlung.org.uk/blog/advice-support/know-your-rights-what-do-if-you-have-damp-mould-rented-home

8. London Fire Brigade – Safe Use of Dehumidifiers & Ventilation Advice

Useful because many people misuse heaters or dehumidifiers while trying to “dry out” a home.
🔗https://www.london-fire.gov.uk/safety/

9. Royal Institution of Chartered Surveyors

The Royal Institution of Chartered Surveyors (RICS) is the global professional body setting standards for land, property, construction and the built environment. Its members help ensure that buildings and infrastructure are safe, well-managed and sustainable, providing trusted expertise for governments, industry and the public.

https://www.rics.org/consumer-guides/damp-and-mould

Optional extras (carefully chosen):

World Health Organization – Indoor Dampness & Health Review

A global evidence assessment → helps debunk myths about “toxic mould” testing.
🔗 https://www.who.int/publications/i/item/9789289041683

Important reassurance you can give people

These sources are aligned on three key points:

✔ Mould exposure can worsen asthma, allergies and respiratory illness.

Especially in children, older adults, and people with chronic lung conditions (like ABPA, CPA, bronchiectasis).

**✔ Mycotoxins in UK homes are not a common cause of chronic, systemic illness.**

Reputable agencies (NHS, UKHSA, WHO) do not support “mycotoxin testing” or expensive “detox” treatments.

✔ Fixing the building is the most important treatment.

Ventilation, reducing humidity, removing contaminated soft furnishings, and remediation are the real interventions.

by GAtherton

Aspergillosis Research Highlights — Week in Review (Last 7 Days: Week 50)

Seven key publications: pathogenicity, diagnostics, resistance, treatment, maxillofacial disease, and ABPA in COPD.

1. Comparative Overview of A. fumigatus, A. flavus, and A. niger

Rafique et al., J Infect Public Health, 2025
DOI: 10.1016/j.jiph.2025.103070

What this adds

A major comparative review (2000–2025) of the three most clinically relevant Aspergillus species.
Highlights broad clinical spectrum: allergy → chronic disease → invasive aspergillosis.
Identifies species-specific concerns:
- A. fumigatus: globally dominant, rapidly evolving triazole resistance.
- A. flavus: important in warmer climates; high aflatoxin relevance.
- A. niger: relatively lower virulence but significant in sinus disease.
Public health message: surveillance gaps persist, especially for non-fumigatus species.

Why it matters

A strong reference paper supporting the WHO prioritisation of Aspergillus, and reinforcing the need for:

Better diagnostics
Species-level identification
Environmental resistance monitoring

2. GFP Fusion Protein Proteolysis in A. fumigatus

Paul & Moye-Rowley, G3 (Bethesda), 2025
DOI: 10.1093/g3journal/jkaf295

What this adds

Fundamental molecular biology study revealing regulated degradation pathways of green fluorescent protein (GFP) fusion proteins inside A. fumigatus.
Demonstrates how the fungus controls protein turnover under stress conditions.

Why it matters

Advances tools for fungal cell biology.
Supports drug development by clarifying pathways involved in stress response and antifungal tolerance.
Reinforces WHO’s classification of A. fumigatus as one of the four most critical fungi to study.

3. ABPA in COPD: Case Series + Review

Ren et al., BMC Pulmonary Medicine, 2025
DOI: 10.1186/s12890-025-04027-8

What this adds

11 COPD cases with confirmed Allergic Bronchopulmonary Aspergillosis — highlighting:
- Under-recognition in COPD
- Overlap with chronic bronchitis/bronchiectasis symptoms
- Frequent misdiagnosis as recurrent infections or COPD exacerbations
Provides diagnostic guidance and a literature synthesis.

Why it matters

Significant implications for case finding across the UK.
Supports NAC messaging: ABPA is not only an asthma disease.
Reinforces need for:
- IgE/IgG screening
- Early CT imaging
- Awareness among COPD teams and primary care

4. EL219: Next-Generation Polyene Antifungal

Youssef et al., AAC, 2025
DOI: 10.1128/aac.01400-25

What this adds

Animal model evidence that EL219, a modern polyene, is effective against:
- Triazole-susceptible A. fumigatus
- Azole-resistant isolates
- Difficult species (A. lentulus, A. calidoustus)

Why it matters

Highly relevant to rising global antifungal resistance.
Early indication that EL219 may fill a clinical gap similar to (or complementary to) olorofim and fosmanogepix.
Suggests strong activity even in immunosuppressed models.

5. Misidentification & Triazole Resistance in Aspergillus tubingensis

Wang et al., JAMA Network Open, 2025
DOI: 10.1001/jamanetworkopen.2025.43630

What this adds

Large Southern California population study showing:
- Frequent misidentification of A. tubingensis as A. niger.
- Notable azole resistance rates in correctly identified isolates.
Stresses need for genomic sequencing or MALDI-TOF with updated libraries.

Why it matters

Strong evidence that misidentification leads to:
- Inappropriate antifungal therapy
- Poor outcomes
Supports calls for expanded diagnostic reference services such as MRCM.

6. 50-Year Review of Oral Fungal Infections in Thailand

Kosanwat et al., Clinical Oral Investigations, 2025
DOI: 10.1007/s00784-025-06685-8

What this adds

Longitudinal study: 29% of deep infections involved aspergillosis.
Mean age 62 → older adults most affected.
Many cases were mucormycosis, histoplasmosis, or aspergillosis presenting late.

Why it matters

Shows that oral/maxillofacial fungal disease remains under-recognised globally.
Relevant to dental teams → better imaging + biopsy protocols needed.
May help NAC/CARES identify referral pathways from dental medicine.

7. Management of Maxillary Sinus Aspergillosis with Implants

Khoury et al., Int J Oral Implantol, 2025

What this adds

Real-world 3–10 year follow-up of 11 patients.
Standardised approach:
- Surgical clearance
- Antifungal therapy
- Successful implant-prosthetic rehabilitation

Why it matters

Demonstrates excellent long-term outcomes when sinus aspergillosis is properly treated.
Practical implications for:
- ENT surgeons
- Oral surgeons
- Implant dentistry
Supports inclusion of aspergillosis in sinus disease differential diagnosis.

Cross-Cutting Themes Emerging This Week

1. Under-recognition and misidentification

ABPA in COPD
Misidentified A. tubingensis
Asymptomatic sinus disease
Oral/maxillofacial deep fungal infections

→ Key NAC message: We are missing cases in primary care, COPD clinics, ENT, and dentistry.

2. Antifungal resistance remains a central threat

Contemporary reviews of species-specific resistance patterns
EL219’s promise against resistant species
Misidentification leading to incorrect susceptibility assumptions

3. Need for better diagnostics and reference centres

Species-level identification is essential
Supports arguments for expansion of MRCM-style national services

4. The clinical spectrum is broad

From allergy (ABPA in COPD) → chronic sinus disease → deep oral infections → invasive pulmonary aspergillosis.
This reinforces the message: aspergillosis is multi-specialty, not confined to respiratory medicine.

Weekly NAC/MRCM Take-Home Messages

COPD teams should screen for ABPA more frequently—especially in patients with recurrent “infective exacerbations.”
Species-level identification is increasingly important; misidentification contributes to treatment failure.
New antifungals like EL219 show promise against resistant strains including A. lentulus.
Dental and ENT teams need better awareness: sinus and oral fungal infections remain overlooked but treatable.
Global reviews show growing public health significance of Aspergillus species—aligning with WHO priorities.

by GAtherton

Biofilms: what they are, why they cause persistent infection, and how research is changing treatment

1. What exactly is a biofilm?

A biofilm is a structured community of microbes—bacteria, fungi, or a mixture—that attaches to a surface and produces a self-generated protective matrix.

The building blocks

Biofilms contain:

Cells: e.g., Aspergillus fumigatus, Pseudomonas aeruginosa, Staphylococcus aureus
Extracellular polymeric substances (EPS):
- Sticky sugars (polysaccharides)
- Proteins
- DNA released from dead cells (eDNA)
- Lipids
  These form the thick “slime” layer.

Microbial ‘specialisation’

Within a biofilm, microbes change behaviour:

Some become slow-growing persister cells, which survive drug exposure.
Others produce signalling molecules (“quorum sensing”) to coordinate defence systems.
The deeper layers become low-oxygen and acidic, making antifungals and antibiotics less effective.

Where do biofilms form in lung disease?

In bronchiectatic airways, where mucus stagnates
Around Aspergillus cavities in chronic pulmonary aspergillosis (CPA)
In mucus plugs in ABPA
In sinuses of patients with chronic fungal sinusitis
On medical devices (catheters, stents)

2. Why biofilms create so many problems

Biofilm problem 1: Immense drug resistance

Microbes in biofilms can be 100–1,000× more tolerant to antifungals/antibiotics.
This is due to:

EPS matrix blocking drug penetration
Slow metabolic rate → drugs that target growth become less effective
Persister cells surviving even high doses
Enzymes in the biofilm breaking down drugs

Aspergillus biofilms show increased resistance to:

Azoles (itraconazole, voriconazole)
Amphotericin B
Echinocandins to a lesser extent

Pseudomonas biofilms resist:

Ciprofloxacin
Colistin (partially)
Beta-lactams
This helps explain your recent comment about Pseudomonas now being resistant even though you haven’t used ciprofloxacin for years—biofilms drive spontaneous resistance through evolution, stress responses, and gene exchange.

Biofilm problem 2: Immune evasion

Immune cells (neutrophils, macrophages) cannot easily penetrate the EPS layer.
This leads to:

Incomplete clearance → long-term infection
Chronic inflammation → lung damage, fatigue
Continuous mucus production triggered by inflammation

For Aspergillus, the fungus can switch genes on/off to avoid immune detection when it grows as a biofilm-like sheet rather than as airborne spores.

Biofilm problem 3: Mixed infections behave differently

When bacteria and fungi coexist, they interact:

Pseudomonas produces molecules that stimulate Aspergillus regrowth, or vice versa
Each organism’s biofilm strengthens the other
Mixed biofilms activate more intense inflammation
They can shift the entire lung microbiome into a more disease-promoting “ecology”

This is why people with bronchiectasis or ABPA often experience:

Frequent exacerbations
Slow recovery
Mucus plugging
Worsening lung function over time

3. Why people with aspergillosis and bronchiectasis are especially vulnerable

Stagnant mucus

Biofilms love:

Thick mucus
Low airflow
Damp surfaces

All of which are present in:

Bronchiectasis
ABPA (due to mucus plugging)
Chronic pulmonary aspergillosis
Severe asthma with fungal sensitisation (SAFS)

Altered immunity

Long-term steroid use, high IgE, eosinophilia, and chronic inflammation all influence how readily biofilms form and how well the immune system can clear them.

Frequent antibiotic/antifungal exposure

This shapes the microbial community in a way that makes biofilms more likely and more resistant.

4. What we are doing to tackle biofilms

A. Current clinical strategies

1. Airway clearance is the single most effective biofilm disruptor

Physiotherapy techniques that help:

ACTs (Active Cycle of Breathing Techniques)
Oscillating devices (Flutter, Acapella)
Postural drainage
Autogenic drainage
Saline nebulisation

These physically remove biofilms, which no drug can fully achieve alone.

2. Nebulised therapies

Hypertonic saline (3–7%) helps break down mucus and destabilise the EPS matrix
Inhaled antibiotics (tobramycin, colistin, aztreonam) target bacterial biofilms
Nebulised antifungals are being explored, though not yet standard care

3. Anti-inflammatory control

Steroids/biologics help reduce airway swelling and mucus stasis, indirectly reducing biofilm formation.

4. Managing comorbidities

Reducing reflux
Improving sinus clearance
Treating asthma aggressively

All reduce the “fuel” available to biofilms.

B. Research and innovation

1. New antifungals with anti-biofilm activity

Olorofim
Fosmanogepix
Ibrexafungerp

These show better penetration and less susceptibility to biofilm-related resistance.

2. Quorum sensing blockers

Compounds that prevent microbes from “communicating” so they cannot coordinate a biofilm. In trials for Pseudomonas.

3. Enzymes to dissolve the biofilm matrix

Research into:

DNases
Polysaccharide-breaking enzymes
Surfactants

These aim to weaken the EPS “scaffolding”.

4. Microbiome-based approaches

Understanding how lung microbial ecosystems shift in disease could allow:

Removal of harmful species
Strengthening protective species
Reducing biofilm formation overall

5. Combination therapies

Antifungal + antibiotic + mucolytic
is likely the future for patients with mixed fungal–bacterial biofilms.

5. Key takeaways

Biofilms are highly organised microbial fortresses that are difficult for drugs and the immune system to reach.
They cause persistent infection, inflammation, and drug resistance.
In aspergillosis and bronchiectasis, they play a central role in ongoing symptoms and flare-ups.
Airway clearance remains the cornerstone of treatment today.
New antifungals, antibiofilm agents, and microbiome therapies offer real hope for breaking biofilm-related disease cycles.

by GAtherton

Why do some people cough up long, tube-shaped pieces of mucus?

In several chronic lung conditions, the airways can become inflamed and produce thick mucus.
When this mucus sits in the bronchial tubes, it can sometimes harden into a cast shaped exactly like the airway.

People often describe these casts as:

long, ribbon-like or “snakeskin” pieces
rubbery or stretchy
white, yellow, or green
shaped like the inside of a tube

Coughing one up can feel dramatic but is usually a sign that your lungs are finally able to clear a blockage.

**What does it mean if a cast has black flecks or dark spots?**

This can look alarming, but several common, mostly harmless explanations exist.

1. Old or dried blood

Tiny amounts of bleeding from irritated airways can dry and turn:

red → brown → black

This often appears as tiny black dots or threads.

2. Inhaled particles

Dust, soot, pollution, or smoke can get trapped in mucus deeper in the lungs and show up as dark specks.

3. Debris from infection or inflammation

Long-standing inflammation can cause:

darkened mucus fragments
tiny bits of fungal, bacterial or biofilm material
oxidised (darkened) mucus layers

These often look like pepper-like flecks and are not dangerous on their own.

4. Oxidation or ageing of thick mucus

When mucus sits for a long time before it is coughed out, it can become darker in spots.

**When this is usually not worrying**

Black flecks are often harmless when:

the amount is small
the colour change is occasional
you feel better after coughing the cast out
there is no new increase in blood, fever, or breathlessness
this fits your usual pattern of mucus plugging

Most people with chronic airway disease experience occasional colour changes in mucus.

When to mention it to your doctor

You should let your team know if:

black flecks keep appearing repeatedly
you cough up more blood than usual
your breathing worsens suddenly
your sputum smells different
you have fever or chest pain
casts become bigger, more frequent, or harder to clear

These changes do not always mean something serious, but they are worth checking.

Why do casts form in the first place?

Conditions that can cause airway casts include:

Bronchiectasis
ABPA (Allergic Bronchopulmonary Aspergillosis)
Severe or eosinophilic asthma
Chronic infections, including fungal or bacterial
COPD with mucus hypersecretion

Inflammation makes mucus thicker, and narrowed airways make it harder to clear.
Over time, mucus can mould itself into the shape of the airway — becoming a cast.

What to do if you cough one up

Stay calm — this often brings relief.
Take note of its colour and size.
Hydrate well to thin mucus.
Continue your usual airway-clearance technique (physio, nebulisers, saline, etc.)
Let your team know if it is unusual for you.

Final reassurance

Coughing up a long, tube-like piece of mucus can feel shocking, but in most cases it simply means your lungs are clearing a blocked area.
Black flecks are usually:

old blood
trapped dust or soot
dried mucus debris

Most of the time, these findings are not dangerous, but they can give useful clues about airway inflammation.

by GAtherton

**Understanding Your Immune System:

A Simple Guide for Aspergillillosis Patients and Carers**

Part of the Aspergillosis Immune System Knowledge Hub
(See also: Articles 2, 3, and 4)

When you live with aspergillosis, asthma, bronchiectasis, or fungal allergy, the immune system plays a major role in your symptoms and how your condition behaves. This article explains the key parts of the immune system in a clear, accessible way.

🧬 1. B Cells — the Antibody Makers

B cells produce antibodies, which act like “tags” that help the immune system recognise germs.

They make different types, including:

IgE — triggers allergy
IgG — provides long-term immunity and helps diagnose chronic infection
IgA — protects the nose, throat, and gut

In Aspergillosis:

ABPA: B cells overproduce IgE against Aspergillus.
CPA: High Aspergillus IgG helps confirm chronic infection.
SAFS/Bronchitis: Mixed or subtle antibody patterns.

🧠 2. T Cells — the Immune System’s Directors

T cells guide and regulate the immune response.

Types include:

Helper T cells (Th cells): tell B cells what antibodies to make
Killer T cells: destroy infected or damaged cells
Regulatory T cells: calm the immune system and prevent over-reaction

In Aspergillosis:

ABPA: Helper T cells become overactive, driving allergic inflammation.
CPA: T cells attempt to control fungal growth but cannot fully clear it.

🟡 3. IgE — the Allergy Antibody

IgE causes:

wheezing
swelling
itching
mucus production
allergic reactions

In ABPA, IgE levels become very high because the body incorrectly treats Aspergillus as a major allergen.

🟢 4. IgG — the Memory and Detection Antibody

IgG helps the immune system remember past infections.
A raised Aspergillus IgG level is one of the main tests for CPA.

🔥 5. Mast Cells — the Alarm Cells

Mast cells sit in the lungs, nose, sinuses, skin, and gut.
When triggered (often by IgE), they release:

histamine
leukotrienes
inflammatory chemicals

This causes:

wheezing
chest tightness
mucus production
itching or burning sensations
coughing

They are very active in ABPA and severe asthma.

🌈 6. Histamine — Why Symptoms Feel the Way They Do

Histamine release leads to:

swelling and redness
increased mucus
nerve irritation → itch, tickle, burning
airway narrowing → wheeze and breathlessness

This explains why flare-ups can feel sudden or “out of proportion” to test results.

🧩 7. Putting It Together: Immune Pathways in Aspergillosis

Condition	Dominant Antibody	Key Cells	Symptoms Driven By
ABPA	Very high IgE	Mast cells, eosinophils	Allergy, mucus, flare-ups
CPA	Raised IgG	T cells, macrophages	Chronic inflammation, cavities
SAFS/Allergic asthma	IgE ± eosinophils	Mast cells, eosinophils	Wheeze, mucus, sensitivity
Aspergillus bronchitis	Variable	Neutrophils, airway cells	Cough, sputum, recurring infections

Understanding these pathways helps you and your clinical team choose the right treatments.

Next articles:

by GAtherton

Why can Pseudomonas become resistant even when you haven’t taken antibiotics for years?

For people with aspergillosis, asthma, and bronchiectasis, it’s very common to live with long-term Pseudomonas in the lungs.
Hearing that it has become resistant to ciprofloxacin feels frightening, but this does not mean you’ve done anything wrong — or that you’re running out of options.

Here’s why resistance happens:

1. Bronchiectasis airways allow bacteria to settle long-term

The widened, inflamed airways seen in ABPA and bronchiectasis create places where mucus pools and bacteria survive for months or years.

2. Pseudomonas forms “biofilms”

These are sticky layers that protect the bacteria from antibiotics.
Inside them, Pseudomonas can:

swap resistance genes
slowly mutate
become harder to kill

This can happen even without taking antibiotics recently.

3. Your sputum contains a mixture of different strains

Some strains may have been slightly resistant for years.
One strain can suddenly become dominant — and that’s what shows up on the lab test.

So developing resistance is normal in chronic lung disease and not a sign your lungs have suddenly worsened.

Does ciprofloxacin resistance mean IV antibiotics are the only option now?

No — not automatically.
Your team will look at the full sensitivity report to see what is still effective.

Possible options include:

1. Nebulised antibiotics

These are widely used in people with ABPA + bronchiectasis because they act directly in the lungs with fewer body-wide effects.
Common inhaled antibiotics:

Colistin
Tobramycin
Aztreonam

These often have very little impact on the gut microbiome.

2. Other oral antibiotics (if sensitive)

Sometimes alternatives still work, depending on the report.

3. A “suppression” plan

Some patients use inhaled antibiotics on a regular cycle to keep symptoms down and reduce flare-ups.

IV antibiotics are only needed if:

symptoms become severe
there are no suitable oral or inhaled options
your team wants a stronger “clean-out” of the lungs

Even then, it does not mean hospital admission — many patients receive IVs at home.

If IV treatment is recommended

It’s completely normal to feel nervous — especially if you’ve never had IV therapy before.

But here is the part most people find reassuring:

1. The treatment is closely monitored

Blood tests, kidney checks, and hearing tests are routine.
Your team will adjust the dose if needed.

2. Many people feel significantly better afterwards

Patients often say their lungs feel “lighter,” with:

less sputum
easier breathing
fewer flare-ups
more energy

3. Home IV therapy is common

Specialist nurses can support you, and it’s usually temporary.

What about the microbiome?

This is a valid concern, especially for people with long-term lung conditions.

Good news:

Nebulised antibiotics hardly affect the gut microbiome at all.
IV antibiotics mainly affect it short-term, and most people return to baseline once treatment stops.
Your team can help you protect your gut during treatment.

What should you do next?

Here’s a simple plan:

Ask for the full sensitivity report.
There may be several antibiotics still effective.
Discuss inhaled options.
Many ABPA/bronchiectasis patients manage very well with nebulised therapy.
Ask whether this resistance result needs repeating.
Sometimes it reflects one resistant pocket within the biofilm rather than the whole population.
Talk through what an IV plan would look like
— including home options and support.

Final reassurance

Ciprofloxacin resistance is extremely common in people with aspergillosis, ABPA, and bronchiectasis.
It does not mean:

your disease is progressing
you caused the resistance
you are running out of treatment
IV is your only option

It simply reflects how clever Pseudomonas is — and how complex airways behave in chronic aspergillosis.

Your team will still have a range of effective treatments.

by GAtherton

**Where Do All These Immune Cells Live, and Where Are They Made?

A Simple Guide for Patients and Carers**

When we talk about T cells, B cells, eosinophils, mast cells, IgE, IgG, and other immune system parts, it’s natural to wonder:

Where are these cells actually made?
Where do they live in the body?
Where do they go when you’re ill?

Here is a simple explanation.

🧱 1. Most immune cells are MADE in the bone marrow

Bone marrow is the soft tissue inside your bones (especially the pelvis, spine, ribs, skull, and sternum).

Inside this marrow are stem cells, which are the “mother cells” that can turn into:

red blood cells
white blood cells
platelets

Almost all immune cells begin their life in the bone marrow, including:

B cells
eosinophils
mast cell precursors
neutrophils
monocytes
basophils

The bone marrow is like the main factory for your entire immune system.

🫀 2. T cells are trained in the thymus

After T cells are created in the bone marrow, they travel to the thymus — a small organ behind the breastbone.

The thymus is like a school where T cells learn:

what is safe
what is dangerous
how to avoid attacking the body itself

This training is essential for preventing autoimmune diseases.

After training, T cells spread through the body.

🩸 3. Immune cells travel in the blood and lymph

Once made, immune cells circulate around the body like security guards on patrol.

They travel through:

Blood

This carries cells quickly to any part of the body.

Lymph system

A drainage and communication network that runs alongside the bloodstream.

Lymph nodes (in the neck, armpits, groin) act like checkpoints, where:

immune cells meet
information is exchanged
inflammation signals get amplified

If your glands are swollen during illness, that’s because immune cells are gathering there.

🫁 4. Many immune cells live in tissues, not just in the blood

Some immune cells settle in certain places:

Mast cells

Live in tissues such as:

lungs
sinuses
skin
gut
blood vessels

They wait there like "alarm sensors," ready to react if something enters the tissue.

Macrophages

Live in tissues and “eat” germs.

Eosinophils

Move into tissues during allergy or asthma flare-ups.

T cells and B cells

Live in:

lymph nodes
spleen
tonsils
tissues throughout the body
airway lining in people with asthma or ABPA

🧫 5. Where antibodies (IgE, IgG) come from

Antibodies are made by plasma cells, which are specialised B cells.

These plasma cells usually live in:

the bone marrow
lymph nodes
spleen
airway tissues (especially in chronic inflammation)

So:

IgE is mostly made in tissues involved in allergy (lungs, sinuses, skin).
IgG is made in bone marrow and lymph tissues to provide long-term protection.

Antibodies then circulate in the blood, ready to recognise anything they have been trained to detect.

🧬 Where these cells actually are, in simple terms:

Immune Cell / Antibody	Where It Is Made	Where It Lives / Works
B cells	Bone marrow	Lymph nodes, blood, tissues
Plasma cells (make antibodies)	Bone marrow / lymph nodes	Bone marrow, tissues
T cells	Bone marrow → trained in thymus	Blood, lymph nodes, organs
IgE antibodies	Plasma cells in tissues	Lungs, skin, blood
IgG antibodies	Plasma cells	Blood (body-wide protection)
Eosinophils	Bone marrow	Blood → lungs during flare-ups
Mast cells	Bone marrow (as precursors)	Lungs, skin, sinuses, gut
Neutrophils	Bone marrow	Blood → infection sites

🧠 6. How this applies to aspergillosis

In ABPA

IgE is made in the lung tissues.
Mast cells in the lungs release histamine.
Eosinophils move from the bone marrow into the airways.

In CPA

IgG is made in bone marrow in response to chronic infection.
T cells gather in lung cavities and damaged tissue.

In fungal asthma / SAFS

Mast cells and eosinophils in the lungs respond strongly to triggers.

Understanding where these cells come from and where they live helps explain why:

symptoms can flare suddenly
blood test levels change
treatments like steroids or biologics work
inflammation can persist even when scans look stable

🏁 Simple takeaway

Your bone marrow makes most of your immune cells.
Your thymus trains T cells.
Immune cells patrol your blood and lymph system.
Many immune cells live long-term in your lungs, skin, and tissues.
Antibodies are made by plasma cells in bone marrow and lymph nodes.
In aspergillosis, the lungs become a major “immune battlefield.”

Next articles:

by GAtherton

**Eosinophils and Type-2 Inflammation:

What Aspergillosis Patients Need to Know**

Part of the Aspergillosis Immune System Knowledge Hub

Eosinophils are a type of white blood cell central to allergy, asthma, and ABPA. They play a major role in symptoms, flare-ups, mucus plugging, and treatment responses.

This article explains eosinophils in simple terms.

🧬 1. What Are Eosinophils?

Eosinophils are immune cells filled with granules containing powerful enzymes.
They normally help:

fight parasites
regulate allergic inflammation
repair tissues
produce important immune signals

But in excess, they can cause damage — especially in the lungs.

🔥 2. Eosinophils in the Lungs

Activated eosinophils release their granules into airway tissues, causing:

swelling
increased mucus
airway narrowing
cough sensitivity
wheezing
breathlessness

This makes them key players in allergic and fungal-related lung disease.

🌟 3. Eosinophils in ABPA

Eosinophils are highly active in ABPA.

ABPA involves a strong “type-2” allergic response to Aspergillus, including:

high IgE
mast cell activation
large numbers of eosinophils
thick, sticky mucus
airway obstruction
repeated flare-ups

Eosinophils contribute significantly to long-term lung damage if not controlled.

🌬 4. Eosinophils in Severe Asthma and SAFS

In severe or allergic asthma:

eosinophils can be persistently high
they drive airway swelling
they increase sensitivity to triggers
they worsen recovery after infection

In SAFS, eosinophils may be moderately raised but symptoms can still be severe.

🦠 5. Eosinophils in CPA

In CPA, eosinophils are not usually the dominant cell, but they still matter when patients also have:

asthma
ABPA overlap
fungal allergy
airway hypersensitivity
steroid withdrawal flare-ups

🔗 6. How Eosinophils Link to Other Immune Cells

They interact with:

IgE → recruits eosinophils
T-helper cells (Th2) → tell bone marrow to make more
Mast cells → release histamine that pulls eosinophils into tissues
Airway lining cells → release distress signals

This is why severe allergic pathways often involve all three:
IgE → mast cells → eosinophils

💊 7. Treatments That Target Eosinophils

✔ Steroids (oral or inhaled)

Suppress eosinophil activity.

✔ Biologics

Directly reduce eosinophils:

Mepolizumab (anti-IL-5)
Benralizumab (anti-IL-5 receptor)
Reslizumab (anti-IL-5 infusion)

Reduce eosinophil recruitment:

Dupilumab (anti-IL-4/IL-13)
Tezepelumab (broad upstream suppression)

These can transform life for patients with severe asthma or ABPA.

🧠 8. Summary

Eosinophils are key drivers of:

flare-ups
mucus plugging
wheeze
breathlessness
airway damage

Understanding them helps patients:

interpret blood tests
understand biologic treatments
recognise flare-up patterns
manage ABPA and asthma more confidently

Next articles:

by GAtherton

**What Happens in Autoimmune Disease?

(Explained with Addison’s Disease)**

Part of the Aspergillosis Immune System Knowledge Hub

Autoimmune disease occurs when the immune system mistakenly attacks the body’s own tissues. This is different from allergy, infection, or inflammation caused by fungal disease. Addison’s disease is a clear example of autoimmunity and helps explain how this process works.

❌ 1. Autoimmunity = Loss of Immune Tolerance

In autoimmune disease:

the immune system starts recognising the body’s own tissues as “foreign”
T cells and B cells become misdirected
autoantibodies form
inflammation destroys healthy cells

This process develops over months or years.

🧬 2. What Specifically Happens in Addison’s Disease?

Addison’s disease is caused by an autoimmune attack on the adrenal cortex, the part of the adrenal gland that makes:

cortisol
aldosterone
DHEA (adrenal androgens)

The steps include:

1. Loss of tolerance
The immune system mistakenly targets adrenal enzymes (especially 21-hydroxylase).

2. Autoantibodies form
These can be detected in blood tests.

3. Cytotoxic T cells attack adrenal tissue
Gradually destroying hormone-producing cells.

4. Hormone levels fall
Leading to:

severe fatigue
weight loss
low blood pressure
salt loss
nausea
risk of adrenal crisis

Addison’s must be treated with lifelong hormone replacement.

🔄 3. Why Does Autoimmunity Happen?

Factors include:

✔ Genetic susceptibility (HLA types)

✔ Prior viral infection or severe inflammation

✔ Stressful life events

✔ Regulatory T-cell failure

✔ Microbiome disruption

✔ Hormonal influences

Importantly:
Autoimmune disease is never the patient’s fault.

🆚 4. How Autoimmunity Differs from Aspergillosis

Aspergillosis	Autoimmune Disease
Driven by external organism (Aspergillus fungus)	Driven by immune system attacking “self”
ABPA → IgE allergies; CPA → IgG infection response	Autoantibodies + T-cell attack
Treatment aims at fungus + inflammation	Treatment replaces missing hormones
Damage = collateral	Damage = direct

Some patients live with both conditions (e.g., ABPA + adrenal insufficiency), but they arise via very different mechanisms.

🧠 5. Key Message

Autoimmune disease results from a failure of immune tolerance, not from weakness, lifestyle, or exposure. Understanding this helps patients feel more in control and reduces self-blame.

Next articles:

by GAtherton

**How the Immune System Knows What Is “Self”:

A Patient-Friendly Explanation**

Part of the Aspergillosis Immune System Knowledge Hub

Your immune system must be aggressive enough to fight infection — yet gentle enough not to damage your own organs. To achieve this balance, it uses several sophisticated systems to distinguish “self” from “non-self.”

🆔 1. Identity Badges on Every Cell (MHC)

All your cells display special proteins called MHC molecules, which act like ID badges.

They say:
“I belong to this body — do not attack me.”

Immune cells constantly check these badges.

Normal MHC → safe
Missing/damaged MHC → suspicious
Viral or fungal proteins presented on MHC → attack triggered

🧪 2. Immune Training in the Thymus

T cells undergo training in the thymus, where:

harmful T cells that attack your own tissues are destroyed
safe T cells are allowed to mature
tolerance is established early in life

This is called central tolerance.

🛡 3. Regulatory T Cells — the Immune “Brakes”

These cells prevent overreaction and calm inflammation.
They stop the immune system attacking:

your lungs
your adrenal glands
your skin
your nerves
any part of your own body

If regulatory T cells fail, autoimmune disease can develop.

🚨 4. Danger Signals — The Immune System Reacts to Threats, Not Just Foreign Material

The immune system does not attack everything foreign.
It attacks things that appear:

dangerous
infected
damaged
inflamed

This is why harmless substances (pollens, dust, Aspergillus spores) can become allergens — the immune system labels them incorrectly.

🦠 5. The Microbiome Helps Train Immune Tolerance

Healthy bacteria in the gut, skin, and lungs help the immune system learn:

what to attack
what to ignore
how strongly to react

A disrupted microbiome can increase the risk of allergy and autoimmunity.

🧠 6. Why This Matters for Aspergillosis Patients

Understanding immune tolerance helps explain:

why some people get allergy (ABPA)
why some people get chronic infection (CPA)
why a few people develop autoimmune issues, including Addison’s or thyroid disease
how treatments such as biologics work
why inflammation can flare even without new infection

Next articles:

by GAtherton